A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
Active, no longer recruiting
Phase of Trial: Phase III/IV
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TOPAZ
- Sponsors Sanofi Genzyme
- 19 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2020.
- 19 Aug 2016 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
- 04 Jul 2016 Planned End Date changed to 1 Jul 2016.